Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
PHAR Quote, Financials, Valuation and Earnings
Last price:
$17.95
Seasonality move
:
-2.42%
Day range:
$17.21 - $18.10
52-week range:
$7.50 - $18.12
Dividend yield:
0%
P/E ratio:
1,265.04x
P/S ratio:
3.41x
P/B ratio:
4.68x
Volume:
15.7K
Avg. volume:
22.3K
1-year change:
71.47%
Market cap:
$1.2B
Revenue:
$296.7M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 11.23% | -90.74% | $31.00 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $1,010.28 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -7.07% | -135.86% | $97.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.78 | -- | -4.68% | $46.01 |
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 8.51% | -38.17% | $55.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$18.09 | $31.00 | $1.2B | 1,265.04x | $0.00 | 0% | 3.41x |
|
ARGX
argenx SE
|
$848.48 | $1,010.28 | $52.2B | 43.13x | $0.00 | 0% | 18.10x |
|
MRUS
Merus NV
|
$96.91 | $97.00 | $7.4B | -- | $0.00 | 0% | 121.82x |
|
PHVS
Pharvaris NV
|
$25.93 | $46.01 | $1.7B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$2.17 | $8.88 | $228.6M | -- | $0.00 | 0% | 13.13x |
|
QURE
uniQure NV
|
$25.19 | $55.30 | $1.6B | -- | $0.00 | 0% | 86.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHVS
Pharvaris NV
|
0.19% | 0.173 | 0.04% | 12.56x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Pharming Group NV vs. Competitors
-
Which has Higher Returns PHAR or ARGX?
argenx SE has a net margin of 7.71% compared to Pharming Group NV's net margin of 25.88%. Pharming Group NV's return on equity of 0.39% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PHAR or ARGX?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 71.37%. On the other hand argenx SE has an analysts' consensus of $1,010.28 which suggests that it could grow by 19.38%. Given that Pharming Group NV has higher upside potential than argenx SE, analysts believe Pharming Group NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 ARGXargenx SE15 2 0 -
Is PHAR or ARGX More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock PHAR or ARGX?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or ARGX?
Pharming Group NV quarterly revenues are $96.9M, which are smaller than argenx SE quarterly revenues of $948M. Pharming Group NV's net income of $7.5M is lower than argenx SE's net income of $245.4M. Notably, Pharming Group NV's price-to-earnings ratio is 1,265.04x while argenx SE's PE ratio is 43.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.41x versus 18.10x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M ARGXargenx SE18.10x 43.13x $948M $245.4M
-
Which has Higher Returns PHAR or MRUS?
Merus NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -786.17%. Pharming Group NV's return on equity of 0.39% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About PHAR or MRUS?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 71.37%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.09%. Given that Pharming Group NV has higher upside potential than Merus NV, analysts believe Pharming Group NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 MRUSMerus NV2 13 0 -
Is PHAR or MRUS More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock PHAR or MRUS?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or MRUS?
Pharming Group NV quarterly revenues are $96.9M, which are larger than Merus NV quarterly revenues of $12.2M. Pharming Group NV's net income of $7.5M is higher than Merus NV's net income of -$95.5M. Notably, Pharming Group NV's price-to-earnings ratio is 1,265.04x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.41x versus 121.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M MRUSMerus NV121.82x -- $12.2M -$95.5M
-
Which has Higher Returns PHAR or PHVS?
Pharvaris NV has a net margin of 7.71% compared to Pharming Group NV's net margin of --. Pharming Group NV's return on equity of 0.39% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About PHAR or PHVS?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 71.37%. On the other hand Pharvaris NV has an analysts' consensus of $46.01 which suggests that it could grow by 77.43%. Given that Pharvaris NV has higher upside potential than Pharming Group NV, analysts believe Pharvaris NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 PHVSPharvaris NV8 1 0 -
Is PHAR or PHVS More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHAR or PHVS?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or PHVS?
Pharming Group NV quarterly revenues are $96.9M, which are larger than Pharvaris NV quarterly revenues of --. Pharming Group NV's net income of $7.5M is higher than Pharvaris NV's net income of -$43.4M. Notably, Pharming Group NV's price-to-earnings ratio is 1,265.04x while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.41x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns PHAR or PRQR?
ProQR Therapeutics NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -381.88%. Pharming Group NV's return on equity of 0.39% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About PHAR or PRQR?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 71.37%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 308.99%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group NV, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 PRQRProQR Therapeutics NV7 0 0 -
Is PHAR or PRQR More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock PHAR or PRQR?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or PRQR?
Pharming Group NV quarterly revenues are $96.9M, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. Pharming Group NV's net income of $7.5M is higher than ProQR Therapeutics NV's net income of -$12.9M. Notably, Pharming Group NV's price-to-earnings ratio is 1,265.04x while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.41x versus 13.13x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M
-
Which has Higher Returns PHAR or QURE?
uniQure NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -2175.87%. Pharming Group NV's return on equity of 0.39% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PHAR or QURE?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 71.37%. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 119.54%. Given that uniQure NV has higher upside potential than Pharming Group NV, analysts believe uniQure NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 QUREuniQure NV9 2 0 -
Is PHAR or QURE More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock PHAR or QURE?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or QURE?
Pharming Group NV quarterly revenues are $96.9M, which are larger than uniQure NV quarterly revenues of $3.7M. Pharming Group NV's net income of $7.5M is higher than uniQure NV's net income of -$80.5M. Notably, Pharming Group NV's price-to-earnings ratio is 1,265.04x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.41x versus 86.07x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M QUREuniQure NV86.07x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
